Faeth Therapeutics, Inc.
NASDAQ: FTH0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Capital Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Anand Parikh
- Employees
- 29
- Headquarters
- Rockville, United States
- IPO year
- 2014
- Market cap
- $32.9M
- Website
- https://www.faeththerapeutics.com
Loading FTH…
Loading profile data…Frequently asked questions about FTH
What does Faeth Therapeutics, Inc. (FTH) do?
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
Where does FTH trade?
Faeth Therapeutics, Inc. (FTH) trades on the NASDAQ Capital Market.
What sector is FTH in?
Faeth Therapeutics, Inc. (FTH) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Faeth Therapeutics, Inc.?
Anand Parikh is the chief executive officer of Faeth Therapeutics, Inc. (FTH).
Where is Faeth Therapeutics, Inc. headquartered?
Faeth Therapeutics, Inc. is headquartered in United States.
Does FTH pay a dividend?
Faeth Therapeutics, Inc. (FTH) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did FTH go public?
Faeth Therapeutics, Inc. (FTH) completed its initial public offering in 2014.